Molecular Epidemiology of HCV RNA Genotype-3 in Dhaka City, Bangladesh

Abstract

Hepatitis C virus (HCV) is a causative agent that causes chronic liver diseases worldwide. It is a little, enclosed, single-stranded ribonucleic acid (RNA) virus. The recognition of the pathogenic HCV genotype is critical for the remedy of its sufferers. The aim of this study was to identify the HCV RNA genotype to decide the correct treatment of hepatitis C positive sufferers in Bangladesh. Blood samples were collected from 390 individuals and isolated RNA (60 µg) from blood plasma. Extracted RNA was used for quantitative HCV RNA, and complementary DNA (cDNA) was prepared by polymerase chain reaction (PCR) conducted by reverse transcriptase enzyme. This cDNA amplified in multiplex by RT-PCR, which was performed with specific set of primers. The HCV RNA genotype was detected 297 of 390 patients. Of the 390 test samples, 200 (51.28%) samples were from males and 190 (48.71%) were from females, with age ranging from 5 to 78 years. In all, 166 of 200 male samples and 131/190 female samples were found positive for HCV. Of these 390 participants included in the study, 213 (54.61%) were identified as genotype 3 positive, 78 (20%) as genotype 1 positive, 6 (1.53%) as genotype 6 positive, and the remaining 93 (23.85%) samples were unclassified due to low/undetected viral load. In this study, we detected the highest percentage (30.89%) of genotype 3 HCV in patients aged 51 to 60 years. The results suggested that genotype 3 HCV is frequently present in Bangladesh and it is usually responses better to interferon therapy. However, genotype 1 and 6 HCV have also been found circulating in this country, which demands longer treatments and effective control measures.

Keywords

Genotypes / cirrhosis / hepatocellular carcinoma / reverse transcription / cDNA / antiviral therapies / viral load

References

[1] Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases 2018;6(13):589-599

[2] Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39(04):1147-1171

[3] Ashraf H, Alam NH, Rothermundt C. et al. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis 2010;10:208

[4] Rockstroh J, Grint D. et al. Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected?. J Int AIDS Soc 2012;15(04):18116

[5] Islam MS, Miah MR, Roy PK. et al. Genotypes of hepatitis C virus infection in Bangladeshi population. Mymensingh Med J 2015;24(01):143-151

[6] Mahtab MA, Rahman S, Karim MF. et al. Epidemiology of hepatitis B virus in Bangladeshi general population. Hepatobiliary Pancreat Dis Int 2008;7(06):595-600

[7] Azim T, Bogaerts J, Yirrell DL. et al. Injecting drug users in Bangladesh: prevalence of syphilis, hepatitis, HIV and HIV subtypes. AIDS 2002;16(01):121-123

[8] Rahman M, Hossain ME, Afrad MH. et al. Hepatitis C virus infections among clients attending an HIV testing and counseling center in Dhaka, Bangladesh. J Med Virol 2018;90(02):383-387

[9] IEDCR; ICDDRB. National HIV Serological Surveillance 2011, Bangladesh: 9th Round Technical Report. Dhaka, Bangladesh: National AIDS/STD Program (NASP), Directorate General of Health Services, Ministry of Health and Family Welfare, Government of the People's Republic of Bangladesh; 2011

[10] Yee LJ, Weiss HL, Langner RG, Herrera J, Kaslow RA, van Leeuwen DJ. Risk factors for acquisition of hepatitis C virus infection: a case series and potential implications for disease surveillance. BMC Infect Dis 2001;1:8

[11] Lapa D, Garbuglia AR, Capobianchi MR, Del Porto P. Hepatitis C virus genetic variability, human immune response, and genome polymorphisms: which is the interplay?. Cells 2019;8(04):305

[12] Cuypers L, Li G, Libin P, Piampongsant S, Vandamme AM, Theys K. Genetic diversity and selective pressure in hepatitis C virus genotypes 1-6: significance for direct-acting antiviral treatment and drug resistance. Viruses 2015;7(09):5018-5039

[13] Islam MJ, Habib MA., et al. Prevalence of Hepatitis C Virus Genotypes in Bangladesh. Paper presented at: Proceeding of the 13th Annual Scientific Conference ICDDRB Dhaka. March 14-17, 2011; Dhaka, Bangladesh

[14] Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016;22(34):7824-7840

[15] Petruzziello A, Sabatino R, Loquercio G. et al. Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy. PLoS One 2019;14(02):e0212033

[16] Messina JP, Humphreys I, Flaxman A. et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61(01):77-87

[17] Jobayer M, Afroz Z. et al. Hepatitis: knowledge and awareness among the infected population. Bangladesh Med Res Counc Bull 2017;43(03):126-130

[18] Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000;13(02):223-235

[19] Navaneethan U, Kemmer N, Neff GW. Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol 2009;2(05):287-302

[20] Nouroz F, Shaheen S. et al. An overview on hepatitis C virus genotypes and its control. Egypt J Med Hum Genet 2015;16:291-298

[21] Lee YS, Yoon SK, Chung ES. et al. The relationship of histologic activity to serum ALT, HCV genotype and HCV RNA titers in chronic hepatitis C. J Korean Med Sci 2001;16(05):585-591

[22] Forns X, Maluenda MD, López-Labrador FX. et al. Comparative study of three methods for genotyping hepatitis C virus strains in samples from Spanish patients. J Clin Microbiol 1996;34(10):2516-2521

[23] Nagayama K, Kurosaki M, Enomoto N, Miyasaka Y, Marumo F, Sato C. Characteristics of hepatitis C viral genome associated with disease progression. Hepatology 2000;31(03):745-750

[24] Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138(02):447-462

[25] Pawlotsky JM, Prescott L, Simmonds P. et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol 1997;35(07):1734-1739

[26] Frank C, Mohamed MK, Strickland GT. et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355(9207):887-891

[27] Albadalejo J, Alonso R, Antinozzi R. et al. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 1998;36(04):862-865

[28] Ali S, Ahmad A, Khan RS. et al. Genotyping of HCV RNA reveals that 3a is the most prevalent genotype in Mardan, Pakistan. Adv Virol 2014;2014:606201

[29] Ali A, Nisar M, Ahmad H, Saif N, Idrees M, Bajwa MA. Determination of HCV genotypes and viral loads in chronic HCV infected patients of Hazara Pakistan. Virol J 2011;8:466

[30] Bell H, Hellum K, Harthug S. et al. Genotype, viral load and age as independent predictors of treatment outcome of interferon-α 2a treatment in patients with chronic hepatitis C. Construct group. Scand J Infect Dis 1997;29(01):17-22

[31] Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(04):1333-1342

RIGHTS & PERMISSIONS

2023 Global Medical Genetics